Resistance to tPA-induced fibrinolysis and activation of coagulation is present in autoimmune bullous diseases of the skin.

Competing Interests: Declaration of competing interests C.D.B. and H.B.M. have patents issued or pending related to coagulation/fibrinolysis diagnostics, and H.B.M. is an inventor on US11137409B2 that pertains to the tPA-challenged thrombelastogram used in this study. C.D.B. and H.B.M. have previously received grant support from Genentech, Inc. C.D.B. has received grant support from Werfen and consulting fees from Atheneum Partners. H.B.M. has received grant support from Haemonetics, Hemosonics, Stago Diagnostica, and Instrumentation Laboratories/Werfen. All other authors have nothing to disclose. Funding information This study was supported in part by the Nebraska Research Initiative/Faculty Collaboration Initiative (to E.X.W., C.D.B., X.C., and C.J.G.), National Institute of Allergy and Infectious Diseases grant R01-AI165666 (to E.X.W.), and National Institute of General Medical Sciences grant P20-GM152326 (to C.D.B.).